Orforglipron — reference

Orforglipron: oral non-peptide glp-1 receptor agonist, approximate mass —, Suitable for once-daily oral dosing half-life. Identity, evidence base, analytical considerations and limitations.

Scope

A maintained identity and evidence reference for Orforglipron. It is deliberately narrow: what the molecule is, what has been published about it, and what an analytical report on it can and cannot establish. It contains no dosing recommendations and is not advice about anyone's care.

Where a figure is approximate this page says so. Where something is unknown, it says that instead of filling the gap.

Identity

Masses quoted here are approximate and are given for orientation when reading an analytical report. For a mass-error calculation, use the exact monoisotopic mass computed from the elemental composition rather than a rounded figure from a reference page, including this one.

What it is

Orforglipron is a small molecule rather than a peptide. That changes almost everything about it pharmaceutically: no absorption enhancer is required, no fasting window is imposed by the formulation, and manufacturing is chemical synthesis rather than peptide synthesis.

Because it is not a peptide, none of the analytical conventions on this site transfer to it. A reversed-phase peptide purity method is not the right tool and the identity confirmation looks completely different.

Evidence base

Published studies and programmes most relevant to this compound:

• Orforglipron phase 2 obesity
• Orforglipron phase 2 type 2 diabetes
• ATTAIN and ACHIEVE programmes (ongoing)

The phase 2 results were sufficient to justify a large phase 3 programme. Phase 3 is ongoing and this page will not carry results it does not have.

Individual digests for several of these are maintained separately in this commons and are linked from the evidence category. A digest is a summary with its criticisms attached; it is not a substitute for reading the paper.

Analytical considerations

Reversed-phase HPLC with ultraviolet detection at 214 nm is the usual purity method, and electrospray mass spectrometry the usual identity method. A purity figure is an area percentage at a stated wavelength under a stated gradient, and it is not interchangeable with a content determination.

Three things a purity assay on this compound will not tell you: how much peptide is in the container (that requires a content assay), what the counter-ion is (that requires ion chromatography or NMR), and whether anything is present that does not elute under the method used.

See Reversed-phase HPLC for peptides and LC-MS identity confirmation for the method detail.

Status and legality

Investigational; phase 3 ongoing.

Material sold as research-use-only is not a licensed medicine, whatever it contains and however good its certificate is. That is a statement about regulatory status rather than about quality, and it is true of high-purity material as much as of poor material.

Limitations of this page

This is a reference page maintained by volunteers, reviewed on the date shown, and it will be out of date at some point after that date. It summarises published work rather than reproducing it, and a summary always loses something. Where the summary and the source disagree, the source is right.

If you find an error, the fastest route to fixing it is a topic in doc review naming the sentence and the source. The maintainers named above are notified.